A quarter of the S&P 500 companies report earnings next week, and that could buffet the market as investors await the July Fed meeting.Market Insiderread more
Iran's Revolutionary Guard said the British tanker, Stena Impero, failed to follow international maritime rules.World Newsread more
Amazon hires Trump-allied lobbyist Jeff Miller as battle for Pentagon contract heats up.Politicsread more
In a series of tweets, the president addressed an unusual controversy stemming from a speech delivered Thursday by New York Fed President John Williams.Marketsread more
"You need to understand that we're about to embark on the busiest week of the year for industrial earnings," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
Boston Federal Reserve President Eric Rosengren is lining up against an apparent push to cut interest rates, telling CNBC in an interview Friday that the central bank can...The Fedread more
The MTA reported that the 1, 2, 3, 4, 5 and 6 trains are all facing delays due to a network communications issue impacting service in both directions, NBC New York reports.Transportationread more
Companies aren't waiting for the U.S.-China trade war to be resolved, says the head of the world's biggest money manager.Investingread more
US officials including Treasury Secretary Steven Mnuchin and White House economic adviser Larry Kudlow will host a meeting at the White House on Monday of semiconductor and...Technologyread more
Trump's constant berating of the Fed and its actions does not influence the central bank's decisions, Boston Fed's Eric Rosengren says.The Fedread more
The lawsuits allege J&J's talc-based baby powder contained asbestos and caused ovarian and other cancers.Health and Scienceread more
Johnson & Johnson reported a better-than-expected rise in quarterly sales, helped by strength in its pharmaceuticals business.
The company's shares were up 2 percent in premarket trading on Tuesday. As of Monday's close, they had gained about 20 percent this year.
J&J, the first major U.S. drugmaker to announce quarterly earnings, raised its 2016 sales forecast to a range of $71.5 billion to $72.2 billion from $71.2 billion to $71.9 billion.
Sales of the maker of medical devices, pharmaceuticals and personal care products rose 3.9 percent to about $18.5 billion from $17.8 billion, a year earlier.
Johnson & Johnson Chief Financial Officer Dominic Caruso said Tuesday the company has developed a broad-based approach that allows it to grow in an evolving and dynamic health care environment.
He told CNBC's "Squawk Box" the company is gaining market share in consumer products and seeing accelerated growth in in its medical devices business, which is currently undergoing a restructuring. Momentum continues in its pharmaceuticals division, as well, he said.
Pharmaceutical sales rose 8.9 percent to $8.6 billion due to increased demand for its Imbruvica cancer drug and Xarelto blood thinner.
Sales of Remicade, J&J's biggest product, rose 6.7 percent to $1.78 billion.
While the company's patent for Remicade expires in September 2018, Caruso said J&J does not anticipate any early launch of biosimilars, which will eventually compete with the product.
However, the company's net earnings fell to $3.997 billion, or $1.43 per share, from $4.516 billion, or $1.61 per share.
Excluding special items, the Band-Aid maker earned $1.74 per share.
Analysts on average had expected a profit of $1.68 per share on revenue of $17.98 billion, according to Thomson Reuters I/B/E/S.
— CNBC's Tom DiChristopher contributed to this report.